ILD Prognostic Biomarker
Interstitial Lung Disease (ILD) Mortality Prediction
DevelopmentActive
Key Facts
Indication
Interstitial Lung Disease (ILD) Mortality Prediction
Phase
Development
Status
Active
Company
About Imvaria
Imvaria, founded in 2019 by physician-engineers from Google and Stanford, is a private, commercial-stage diagnostics company based in Berkeley, California. It has developed Fibresolve, the first FDA-authorized AI diagnostic tool for IPF/ILD, and is expanding its platform to other areas like lung cancer through a strategic collaboration with Mayo Clinic. The company operates a Digital Biomarker Lab, leveraging machine learning to create software-only biomarkers from complex clinical data, positioning it at the intersection of AI, radiology, and precision diagnostics.
View full company profile